• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 5, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

What’s holding up CRISPR-based cures

Bioengineer by Bioengineer
February 15, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The gene-editing tool called CRISPR that can quickly and cleanly remove specific pieces of DNA has revolutionized biotechnology. Many researchers believe the technique could end thousands of ailments. So what's needed to realize CRISPR's potential? Another breakthrough. The cover story in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, runs down the latest attempts to find it.

Ryan Cross, a correspondent for C&EN, notes that CRISPR has led to thousands of scientific papers and a slew of biotech start-ups since its conception in 2012. The appeal of the technique is that it has the potential not just to treat but to cure intractable conditions scientists have long struggled to address, including sickle cell disease, Duchenne muscular dystrophy and cancer. Researchers in China say they have already conducted a human clinical trial that involves removing cells from patients, editing them using CRISPR outside the body, and putting the modified cells back in the body. A team in Pennsylvania is gearing up for a similar clinical trial in the U.S.

However, the technique's greatest promise lies in injecting the editing tool directly into patients. But sneaking the system past the body's defenses and into the cells where it is needed has been difficult. To overcome this challenge, scientists are taking multiple approaches, each of which has its own subset of additional hurdles. Despite the headwinds, researchers say that because the potential payoff would be huge, the pursuit for solutions will undoubtedly continue.

###

The article, "CRISPR's breakthrough problem," is freely available here.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With nearly 157,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact [email protected].

Follow us on Twitter | Facebook

Media Contact

Katie Cottingham
[email protected]
301-775-8455
@ACSpressroom

http://www.acs.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Poor Sleep May Signal Faster Decline in ALS, Large Chinese Cohort Study Finds

Poor Sleep May Signal Faster Decline in ALS, Large Chinese Cohort Study Finds

October 5, 2026
Normal Labs Last Week, Purulent Bile Today: How Severity Rules Decide Cholangitis Care

Normal Labs Last Week, Purulent Bile Today: How Severity Rules Decide Cholangitis Care

October 5, 2026

Lactate Tag on Histones Fuels Drug Resistance in Head and Neck Cancer

October 5, 2026

Leaf Oil from an Overlooked Asian Tree Blocks Bacterial Biofilms and Tyrosinase in New Study

October 5, 2026
Please login to join discussion

POPULAR NEWS

  • Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

    29 shares
    Share 12 Tweet 7
  • Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

    29 shares
    Share 12 Tweet 7
  • Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

    29 shares
    Share 12 Tweet 7
  • New Scale Measures How Ready Nurse Educators Really Are for the AI Era

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone

Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes

Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.